Medical AI Pioneer Dr. Ben Ayed Joins DIAGNOS as Chief AI Scientist to Transform Retinal Disease Detection

2025-12-31 09:55:41

BROSSARD, Quebec – December 16, 2025 – In a significant strategic move to strengthen its leadership in artificial intelligence applications for healthcare, DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) has recruited Dr. Ismail Ben Ayed as Chief Artificial Intelligence Scientist. This appointment marks a pivotal step in the company’s mission to revolutionize early detection of eye-related diseases through cutting-edge AI technology.

A Proven Leader in Medical AI

Dr. Ben Ayed brings extensive expertise to the role. Currently serving as a full-time Professor at the Department of System Engineering at École de Technologie Supérieure (ÉTS) in Montreal, he also directs the LIVIA research center, which specializes in imaging, vision, and artificial intelligence. His career includes a tenure as research scientist at GE Healthcare, and his academic contributions span over 150 peer-reviewed publications focused on deep learning, computer vision, and medical image analysis.

Strategic Focus and Mandate

In his capacity as Chief AI Scientist, Mr. Ben Ayed will drive three key initiatives:

Next-Generation AI Development: Advancing the CARA (Computer-Assisted Retinal Analysis) System platform to enhance diagnostic accuracy and clinical effectiveness in detecting retinal and eye-related diseases
Team Expansion: Building and mentoring an in-house team of AI researchers and scientific professionals to accelerate innovation
Academic and Industry Partnerships: Fostering collaborations across research institutions and industry players to validate and scale AI-driven solutions globally

Why This Appointment Matters

The recruitment of a recognized AI researcher underscores DIAGNOS’ commitment to leveraging machine learning and advanced algorithms for preventative healthcare. Reflecting on the partnership, Dr. Ben Ayed stated: “I am focusing on developing robust, generalizable, and clinically validated AI models that can operate at scale. The opportunity to transform how early retinal disease detection is conducted on a global stage is compelling.”

André Larente, President of DIAGNOS, commented: “Ismail’s depth of knowledge in deep learning and medical imaging technology perfectly complements our vision. Together, we will push the boundaries of what’s possible in AI-assisted diagnostics and enhance outcomes for patients worldwide.”

About DIAGNOS

DIAGNOS stands as a publicly traded Canadian corporation dedicated to harnessing Artificial Intelligence for the early identification of critical eye-related health conditions. By integrating advanced AI into clinical workflows, the company aims to provide healthcare professionals with enhanced diagnostic precision, operational efficiency, and improved patient outcomes across global markets.

This release contains forward-looking statements. Actual results may differ materially from projections. DIAGNOS makes no commitment to update forward-looking information except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider assumes responsibility for the accuracy or adequacy of this release.

For inquiries, contact André Larente, President, DIAGNOS Inc. | Tel: 450-678-8882 ext. 224 | alarente@diagnos.ca

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.